Pharmacogenomic testing promises fewer adverse drug events, better efficacy, and less trial-and-error. Yet many health systems still struggle to move PGx from pilot to routine care. The barriers are real. The fixes are practical. This guide shows how to clear the hurdles with a step-by-step plan, proven governance, and the right tools. Let’s discuss Barriers to Implementing PGx Testing.
Understanding the Barriers to Implementing PGx Testing
Barrier 1: “Is the evidence strong enough for everyday use?”
Clinicians want clear, actionable guidance. They do not want to debate genetics on a busy clinic day. Start where the evidence and actionability are strongest.
What to do
- Anchor your first wave on CPIC Level A or B gene–drug pairs. These guidelines translate genotype into phenotype and give explicit prescribing actions. Build your panel and reports around them.
- Publish a short “why now” note for your clinicians. List the target drugs and expected decisions. Keep it to one page.
Why it works
You reduce noise. You frame PGx as a practical decision aid, not a research exercise. You also align your lab and clinical teams to a common playbook.
Barrier 2: Payer coverage is inconsistent
Coverage varies by region and by plan. Many teams pause here. You do not need to.
What to do
- Map your claims geography against the Medicare MolDX LCD for PGx (L38335) and its companion coding article. These documents define when testing is “reasonable and necessary,” how to document medical necessity, and how to bill. Use this language in your prior-auth and appeals templates.
- For commercial lives, keep a small library of health-plan policies and refresh it quarterly. Use them to guide eligibility rules in your order sets.
Why it works
You standardize eligibility and documentation. You reduce denials. You make finance comfortable with the utilization picture.
Barrier 3: Regulatory uncertainty around LDTs
Teams worry that the regulatory ground is moving. They are right. In 2024 the FDA finalized its policy to phase out broad enforcement discretion for laboratory-developed tests. There is a multi-year timeline with staged expectations that begin in 2025.
What to do
- Give your governance group a one-page timeline of the FDA LDT phase-out policy. Stage 1 starts May 6, 2025 with MDR, complaint files, and corrections/removals. Later stages add registration/listing, labeling, quality-system elements, and some premarket reviews. Assign internal owners for each stage.
- Keep your clinical stakeholders informed. Emphasize that strong quality systems and clear labeling improve trust and adoption.
Why it works
You turn uncertainty into a managed workplan. You also show your clinicians and executives that the program is built to last.
Barrier 4: Privacy and discrimination concerns
Patients and staff often raise questions about genetic privacy. Some fear misuse.
What to do
- Educate with plain language. Explain GINA protections in employment and health insurance. State that HR cannot see genetic results and that participation is voluntary. Include this language in consent and patient-facing materials.
- Clarify that medical PGx results live in the EHR under clinical governance. Create a short FAQ for managers and employees.
Why it works
Clear expectations reduce hesitation. Trust grows when people know who sees what.
Barrier 5: Picking the right alleles and detecting the right variants
Panel design is not trivial. Some genes need structural variant detection. Missing a key allele can give the wrong phenotype.
What to do
- Use the AMP “minimum sets of alleles” to standardize content per gene. Map your design to these lists and publish the mapping.
- Treat CYP2D6 as a special case. Confirm copy-number, hybrid alleles, and gene conversions. Document how your pipeline handles them.
- Run validations with diverse reference materials, not just a single ancestry group.
Why it works
Standard content and robust detection improve concordance, reduce re-tests, and build clinician confidence.
Barrier 6: Health equity and representation
Many PGx datasets under-represent non-European populations. This can widen disparities if you are not careful.
What to do
- Audit allele coverage and performance for your local population mix. Fill gaps with targeted assays where needed.
- Include an “equity check” in every validation. Track actionability across ancestry groups and languages.
- Use staff education to frame PGx as a tool for reducing disparities, not reinforcing them.
Why it works
You reduce misclassification risk. You improve trust in communities that have been historically underserved.
Barrier 7: EHR and LIS integration
Great reports that never reach the point of care do not change prescribing. PDF sprawl kills adoption.
What to do
- Store discrete phenotypes in the EHR. Prefill order sets and trigger clinical decision support for the target drugs.
- Use PharmCAT to convert VCFs into CPIC-aligned phenotypes and structured gene–drug statements that your systems can parse. PharmCAT has a preprocessor, JSON output, and report builders you can adapt.
- Keep one templated clinical report per gene–drug pair. Short. Consistent. Action forward.
Why it works
Clinicians get the right prompt at the right moment. Analytics teams can measure use and outcomes.
Barrier 8: Clinician time and training
Most prescribers will not read a white paper between patients. They need clear next steps.
What to do
- Train with ten-minute, case-based micro-sessions tied to each target drug. Put the CPIC summary table and your local formulary on one slide.
- Publish a “call a friend” workflow. List who to page for tricky results.
Why it works
You respect time. You teach the decision, not the whole field of genomics.
Barrier 9: Preemptive vs reactive testing
Preemptive testing is powerful. It is also hard to start. Reactive testing feels easier but can arrive too late.
What to do
- Start with reactive testing for a few high-impact lines of therapy. Use that volume to prove clinician value and refine workflows.
- Add preemptive testing to standard work where it obviously fits. Examples: behavioral health clinics with high antidepressant use, oncology services using thiopurines or fluoropyrimidines, and cardiology clinics prescribing antiplatelets. Keep eligibility rules tight at first.
Why it works
You learn on real cases. You scale when the wins are visible.
Barrier 10: Program governance and ROI
Leaders ask how PGx improves safety, outcomes, and spend. You need answers that stand up to scrutiny.
What to do
- Define a small set of metrics before launch. Examples: adverse-event rates, therapy switches that follow guidance, time to symptom relief, ED visits, inpatient admits, and adherence proxies. Report quarterly.
- Align your test indications and documentation with MolDX and local plan policies. This reduces denials and clarifies the value story for finance.
Why it works
You measure what matters. You keep clinical, quality, and finance leaders aligned.
Tools that shorten the path from genotype to action
- CPIC. Clinical guidelines with explicit actions. Use CPIC to choose scope, name phenotypes, and align report wording.
- PharmGKB. Curated knowledge, drug-label annotations, and pathways. Use it for education, governance packets, and CDS content.
- PharmCAT. An open tool that turns VCFs into CPIC-aligned phenotypes and machine-readable outputs. Use it to standardize your pipeline and scale.
- ClinPGx. The new clinical hub that integrates CPIC, PharmGKB, and PharmCAT under one roof with more features coming. Use it as the front door for teams and as your version-of-record.
The Bottom Line
You can make PGx routine. Start with high-impact gene–drug pairs that have strong guidance. Standardize allele content and detection. Put discrete phenotypes in the EHR. Train with short cases. Measure outcomes the way finance does. Manage the LDT transition with a calm plan. Keep privacy simple and clear.
Use CPIC for decisions, PharmGKB for knowledge, PharmCAT for translation, and ClinPGx as your front door. The barriers shrink when you align people, process, and data around this stack. Patients feel the difference when the right drug at the right dose becomes the default rather than the exception.
Frequently Asked Questions
Do we need to pause until all FDA LDT milestones arrive?
No. Build a quality system that meets today’s rules and lines up with tomorrow’s stages. Keep a simple tracker for MDR, complaint files, labeling, registration/listing, and any future submissions.
Can we start with “PDF only” reports?
You can. You should not. Add discrete phenotypes as soon as possible. Use PharmCAT outputs to speed the work.
How do we avoid equity pitfalls?
Validate in diverse samples. Cover ancestry-relevant alleles. Watch performance and actionability by group. Update content as needed.
What if clinicians are skeptical?
Lead with a clear “when this, do that” story for three drugs. Share early wins and how they changed care. Tie the program to safety and fewer adverse events.
For more great articles, go here.
